X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x - 44.9 - View Chart
P/BV x 7.4 3.9 192.4% View Chart
Dividend Yield % 0.6 0.3 175.5%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CIPLA
Mar-17
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,589622 255.5%   
Low Rs1,232458 268.8%   
Sales per share (Unadj.) Rs417.5181.9 229.6%  
Earnings per share (Unadj.) Rs56.312.9 437.4%  
Cash flow per share (Unadj.) Rs64.729.3 220.7%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.4 243.2%  
Book value per share (Unadj.) Rs292.9155.7 188.2%  
Shares outstanding (eoy) m119.57804.51 14.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.8%   
Avg P/E ratio x25.142.0 59.7%  
P/CF ratio (eoy) x21.818.4 118.3%  
Price / Book Value ratio x4.83.5 138.8%  
Dividend payout %22.615.5 145.2%   
Avg Mkt Cap Rs m168,653434,516 38.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m9,17126,338 34.8%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m49,915146,302 34.1%  
Other income Rs m1,6452,287 71.9%   
Total revenues Rs m51,561148,589 34.7%   
Gross profit Rs m8,48224,758 34.3%  
Depreciation Rs m1,00613,229 7.6%   
Interest Rs m6711,594 42.1%   
Profit before tax Rs m8,45112,222 69.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,798 89.3%   
Profit after tax Rs m6,73110,354 65.0%  
Gross profit margin %17.016.9 100.4%  
Effective tax rate %19.014.7 129.2%   
Net profit margin %13.57.1 190.5%  
BALANCE SHEET DATA
Current assets Rs m27,06287,370 31.0%   
Current liabilities Rs m15,32433,081 46.3%   
Net working cap to sales %23.537.1 63.4%  
Current ratio x1.82.6 66.9%  
Inventory Days Days6787 76.5%  
Debtors Days Days4162 66.3%  
Net fixed assets Rs m12,610111,567 11.3%   
Share capital Rs m2391,609 14.9%   
"Free" reserves Rs m34,490123,645 27.9%   
Net worth Rs m35,027125,254 28.0%   
Long term debt Rs m1,21236,454 3.3%   
Total assets Rs m54,387209,532 26.0%  
Interest coverage x13.68.7 156.9%   
Debt to equity ratio x00.3 11.9%  
Sales to assets ratio x0.90.7 131.4%   
Return on assets %13.65.7 238.7%  
Return on equity %19.28.3 232.5%  
Return on capital %24.98.5 292.4%  
Exports to sales %12.934.2 37.8%   
Imports to sales %3.18.3 37.0%   
Exports (fob) Rs m6,46150,050 12.9%   
Imports (cif) Rs m1,54012,203 12.6%   
Fx inflow Rs m6,56351,066 12.9%   
Fx outflow Rs m3,01217,678 17.0%   
Net fx Rs m3,55233,388 10.6%   
CASH FLOW
From Operations Rs m7,25923,824 30.5%  
From Investments Rs m1,864-13,127 -14.2%  
From Financial Activity Rs m-9,273-13,239 70.0%  
Net Cashflow Rs m-150-2,478 6.1%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 19, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS